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Abstract
Background:  Peroxisome proliferator-activated receptors (PPARα, PPARγ, and PPARδ) are
physiological sensors for glucose and lipid homeostasis. They are also the targets of synthetic drugs;
such as fibrates as PPARα agonists which lower lipid level, and glitazones as PPARγ agonists which
lower glucose level. As diabetes and metabolic diseases are often associated with high blood
glucose and lipid levels, drugs that activate both PPARα/γ would be a logical approach. But
synthetically developed PPARα/γ dual agonists and glitazones are showing side effects such as
weight gain and edema. Therefore, natural compounds and their close derivatives are focused as
future drugs against metabolic diseases.
Presentation of hypothesis: Docosahexaenoic acid and eicosapentaenoic acid, which are the
fatty acids abundant in fish oil, are traditionally used against metabolic diseases. These fatty acids
act as PPAR agonists that transcript the genes involved in glucose and lipid homeostasis. Present
hypothesis suggests that the derivatives of these fatty acids are stronger PPAR agonists than the
parent compounds. X-ray structures of PPARs indicate that α or β derivatives of fatty acids would
fit into PPARα/γ binding cavity. Therefore, the derivatives will exhibit stronger affinities and
activities than the parent compounds.
Testing of the hypothesis: Ligand binding assays and gene transactivation assays should be
performed to test the hypothesis. Fluorescence-based methods are advantageous in binding assays,
because they were found more suitable for fatty acid binding assays. In transactivation assays, care
should be taken to remove contaminants from recombinant proteins.
Implications of the hypothesis: Present hypothesis is framed on the basis of molecular
structure of natural PPAR agonists. Small structural changes in the molecular structure of fatty acids
have a great influence on activating different PPARs. Therefore, this hypothesis bridges the concept
of natural PPAR agonists and the use of structural information in designing new drugs against
diabetes and metabolic syndrome. The derivatives may also be used as anti-inflammatory and
anticancer agents.
Background
Peroxisome proliferator-activated receptors (PPARs) are
members of nuclear receptor superfamily. Three isotypes
of PPARs (PPARα, PPARγ, and PPARδ) have distinct tissue
distributions, distinct physiological roles, and distinct lig-
and specificities [1]. Activation of PPARα lowers lipid lev-
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els, PPARγ increases insulin sensitivity, and PPARδ
regulates cholesterol and glucose levels [1-3]. PPAR lig-
ands comprise natural or synthetic compounds, including
fatty acids and eicosanoids [4,5]. As synthetic com-
pounds, fibrates are known as PPARα agonists and glita-
zones act as PPARγ agonists [2] (Fig. 1). PPARα/γ dual
agonists have also been developed, because type 2 diabe-
tes and metabolic syndrome are often associated with
high lipid and glucose level in blood.
Antidiabetic glitazones exhibit side effects such as weight
gain, edema, and increased risk of myocardial infarctions
[6,7], which have limited the use of these drugs in diabetic
patients with high lipid levels. The PPARα/γ dual agonists,
which reached clinical trials, have been suspended for
safety issues [8]. Although much information is not avail-
able, these dual agonists are believed to exhibit similar
side effects as with glitazones [2,9]. Bezafibrate, a tradi-
tional PPARα agonist, has recently been identified as a
safe and synthetic pan agonist for all PPAR isotypes
[10,11], although with relatively low potency and low
affinity (Kd ~5 μM for PPARδ [5]).
Development of drugs from natural origin against chronic
diseases, such as metabolic syndrome and diabetes, has
gain focus recently. Because metabolic system can easily
excrete biomolecules and their derivatives, thereby avoid
undesirable effects. Fish oil, which contains docosahexae-
noic acid (DHA) and eicosapentaenoic acid (EPA), is tra-
ditionally used as functional food against metabolic
diseases. These beneficial health effects of DHA and EPA
are thought to arise from their binding and activating
PPARs [12,13]. Phytanic acid, a natural PPAR agonist
from human diet, has also been shown to enhance glu-
cose uptake and thereby increases insulin sensitivity, how-
ever with less capacity to differentiate adipocytes [14]. A
recent study has reported an extract of Fuligo candida, Fuli-
gocandin B, to induce 15-deoxy-Δ12,14 prostaglandin J2
(15d-PGJ2), which is the most potent endogenous PPARγ
ligand [15,16].
The hypothesis of this article is drawn on the assumption
of PPARα/γ dual agonists from naturally originated mole-
cules, that the derivatives of DHA and EPA would show
stronger affinities for PPARs than the parent compounds.
Therefore, these compounds may be used as putative
drugs against diabetes and metabolic syndrome.
Presentation of hypothesis
The hypothesis is based on (a) functional roles of PPARs
– PPAR agonists reduce blood glucose and lipid levels,
and (b) structural details of ligand binding cavity of
PPARs, which suggest how a ligand fits into the cavity.
Functional roles of PPARs
PPARs perform their activities by endogenous ligands pro-
duced by metabolism of fatty acids. Unmetabolized fatty
acids can also act as PPAR ligands. Activities of these lig-
ands vary according to their binding specificities for differ-
ent PPARs, and on distributions of these ligands in
different organs [17]. Because of this diversity, not all
endogenous PPAR ligands are characterized yet. However,
PPAR activities can be summarized as lipid sensors by their
complementary actions. PPARα is expressed mainly in the
tissues with high capacity for fatty acid oxidations, e.g.
liver, heart, skeletal muscle etc. On the other hand, PPARγ
is expressed predominantly in the adipose tissue but is
PPAR agonists Figure 1
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also expressed in immune and inflammatory cells,
mucosa of the colon and placenta. If the fatty acid concen-
trations are increased, PPARα uptakes and oxidizes fatty
acids and their metabolites [18], and PPARγ enhances
storage of fatty acids in the adipose tissue [19]. These com-
bined activities of PPARα and PPARγ cause increased uti-
lization of glucose than fatty acids in the skeletal muscles,
and cause enhanced insulin sensitivity (Fig. 2). Although
PPARδ's role is not well defined, it is also implicated for
fatty acid oxidation [20].
Structure of PPARs
Like other nuclear receptors, 3D structure PPARs consists
of a DNA binding domain in the N-terminus and a ligand
binding domain (LBD) in the C-terminus [21]. In canon-
ical mechanism, ligand binding to PPARs causes confor-
mational changes in the receptor, which release
Complementary actions of PPARα and PPARγ Figure 2
Complementary actions of PPARα and PPARγ. PPARα oxidizes fatty acids in the liver cells, and PPARγ stimulates stor-
age of fatty acids in the adipose tissues. Major events are shown in bold fonts. FA = fatty acid; HDL = High-density lipoprotein; 
VLDL = very low-density lipoprotein.Cardiovascular Diabetology 2008, 7:6 http://www.cardiab.com/content/7/1/6
Page 4 of 6
(page number not for citation purposes)
corepressor and recruit coactivator. Then the receptors
form compulsory heterodimers with another nuclear
receptor, named retinoid X-receptor (RXR), and the result-
ing complex finally bind to DNA of target genes [22] (Fig.
3).
To date, 37 X-ray crystallographically determined struc-
tures of PPAR-LBDs are deposited in the Protein Data
Bank (PDB) in different apo- and holo forms. These struc-
tures shows that the LBD is composed of 13 helices and a
small four-stranded β-sheet (Fig. 3B). The lower part of
LBD contains a Y-shaped cavity with the volume of
1300–1400 Å3 for ligand binding. This cavity includes 34
amino acids; each arm of the cavity is ~12 Å in length.
One of the arms is hydrophilic but the other two are
hydrophobic. While the amino acids in the polar arm
form H-bonds with the ligand polar atoms, those in the
hydrophobic arms form non-specific interactions with
hydrophobic part of the ligands. Across PPARs, ~80%
amino acids in the cavity are conserved, and the overall
size of the cavity is also similar [23]. However, the topol-
ogy is different inside the cavities of different PPARs.
These differences influence ligand specificities. Ligand
binding stabilizes the LBD in the active conformation; as
such coactivator and RXR can bind to the activated LBD
[24].
Fatty acids and their derivatives as PPAR agonists
For centuries, consumption of fatty fish is considered to
protect against metabolic diseases. During early 1970s,
Danish physicians discovered that Greenland Eskimos
consuming fatty fishes exhibited low incidence of heart
diseases and arthritis despite high-fat diet. This finding
suggested beneficial effects of DHA and EPA. Fish oil sup-
plementation successfully passed clinical trials and is now
effectively used for treating metabolic syndrome [25].
Usually, PPAR ligands have three essential parts for opti-
mal binding: (a) polar head group, (b) linker region, and
(c) hydrophobic tail. DHA and EPA have a carboxylic
group which serves as the polar head group, and their long
chains form the required linker and hydrophobic regions.
In addition, X-ray structures of PPARs show some free
spaces proximal to the polar arm of binding cavity [26],
and substitutions at α or β positions on DHA and EPA
would fit into these spaces. Specifically, hydrophobic sub-
Structure and functions of PPARs Figure 3
Structure and functions of PPARs. (A) Functional domains of PPARs. DBD = DNA binding domain; LBD = ligand binding 
domain. Numbers denote residue identity in percent compared to PPARα. (B) LBD of PPARs. PPARα-LBD (PDB ID; 1I7G, 
chain A) is shown with secondary structures; helices in cylindrical form (H: red), β-strands (S: green), 3–10 helix (light blue) 
and loops (cyan). The blue object shows ligand binding pocket. (C) Ligand-dependent activation of PPARs.Cardiovascular Diabetology 2008, 7:6 http://www.cardiab.com/content/7/1/6
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stituents that complement the size of free spaces would be
a choice. However, substituents may not fit into PPARδ
because of its narrow polar regions [27]. Size and hydro-
phobic/hydrophilic ratio of substituents may influence
the ratio of binding between PPARα and PPARγ [28]. A
high PPARα/PPARγ ratio of affinities of putative ligands
would be safer dual agonists, because the side effects are
thought to arise from high PPARγ affinity [2].
Limitation of the hypothesis
EPA and DHA have many beneficial health effects which
are not typical for PPAR ligands. For example, their capac-
ity to reduce coronary heart disease, blood pressure, pri-
mary heart attack and rheumatoid arthritis [29-31] are not
observed with typical PPAR ligands. Also, various devel-
opmental problems including attention-deficit/hyperac-
tivity disorder have been linked to biological deficiencies
in polyunsaturated fatty acids [32]. But these fatty acids do
not show many PPAR effects such as reversing insulin
resistance [33,34], which may occur due to dissociation
between n-3 polyunsaturated fatty acid and lipid metabo-
lism and insulin action in insulin resistant state [35].
Therefore, an interesting observation will be whether sub-
stitutions at α or β positions on these fatty acids impart
such typical PPAR effects.
Testing of hypothesis
Ligand binding assays and gene transactivation assays
would confirm the hypothesis. Ligand binding assays
quantify the binding affinities such as Kd or IC50 values.
Previously published experiments with fatty acids showed
inconsistent binding affinities. Krey et al.[5] reported
binding affinities in 5–10 μM range, while Lin et al[36]
reported this range of 5–17 nM. The latter range corre-
sponds to the intracellular free fatty acid concentrations
which are in the range of 7–50 nM [37]. Until now, no
data are available about the affinities of DHA, DHA deriv-
atives, and EPA derivatives. Therefore, fluorescence-based
methods as used by Lin et al. may provide correct binding
affinities. In transactivation assays of PPARα/γ genes, pre-
cautions should be taken to remove unwanted fatty acids
in the recombinant proteins [38]. In both ligand binding
and transactivation assays, ligands with high ratio of
PPARα/γ affinity and activity should be chosen, which
mean that compounds showing less PPARγ affinities and
activities would be ideal.
Implication of the hypothesis
The ligand binding cavity of PPARs is 3–4 times larger
than the other nuclear receptors, indicating their capabil-
ity to accommodate and bind variety of natural and syn-
thetic lipophilic acids. Many previous studies have
revealed the roles of natural PPAR agonists against specific
diseases. For example, natural PPAR agonists such as 15d-
PGJ2 are emerging as important regulators of immunity
and inflammation [39-41]. 15d-PGJ2 has also been impli-
cated for antitumor activities [42]. PPARα mediates the
anti-inflammatory actions of palmitoylethanolamide, the
naturally occurring amide of palmitic acid and eth-
anolamine [43]. Synthetic PPARγ agonists glitazones have
been reported and used in phase I-II human clinical trials
as anticancer agents [44].
Present hypothesis is framed on the basis of using natural
PPAR agonists that small structural changes in the molec-
ular structure of fatty acids have a great influence on acti-
vating different PPARs [45]. Therefore, this hypothesis
bridges the concept of natural PPAR agonists and the use
of structural information in designing new drugs against
diabetes and metabolic syndrome. The derivatives may
also be used as anti-inflammatory and anticancer agents.
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